Skip to main content
LUMIBIRD logo

LUMIBIRD — Investor Relations & Filings

Ticker · LBIRD ISIN · FR0000038242 LEI · 969500MLJC3ZSZP4L019 PA Manufacturing
Open in API
Filings indexed 560 across all filing types
Latest filing 2025-01-24 Capital/Financing Update
Country FR France
Listing PA LBIRD

About LUMIBIRD

https://www.lumibird.com/en/

LUMIBIRD is a leading specialist in laser technologies with over 50 years of experience. The company designs and manufactures high-performance lasers based on its expertise in three key technologies: solid-state lasers, fiber lasers, and laser diodes. It operates through two primary divisions. The Photonics division provides advanced laser solutions for applications in defense, space, environmental monitoring (including Lidar sensors), industrial manufacturing, and scientific research. The Medical division offers innovative ophthalmological and medical solutions, ranging from diagnostic equipment to laser treatment systems, through brands such as Quantel Medical and Ellex.

Recent filings

Filing Released Lang Actions
LUMIBIRD : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE
Capital/Financing Update Classification · 96% confidence The document is titled "LUMIBIRD : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE" (LUMIBIRD: SEMI-ANNUAL REPORT ON THE LIQUIDITY AGREEMENT). It details the status of the liquidity contract (shares and cash held by the agent) and transaction volumes (purchases and sales) over the second half of 2024 (July 1st to December 31st). This type of regular, periodic disclosure regarding market making or liquidity provision activities is a specific regulatory requirement, often related to market operations rather than core financial performance (like 10-K or IR). Since it is a report detailing specific operational/market data, it is not a general 'Report Publication Announcement' (RPA). It does not fit the definitions for AGM-R, 10-K, AR, ER, or IR. It is a specific regulatory disclosure concerning market activity. Given the options, this detailed report on liquidity contract management and transaction data is best classified as a specific regulatory filing that doesn't fit the other categories, making 'RNS' (Regulatory Filings / miscellaneous regulatory announcements) the most appropriate fallback, although it is a very specific type of filing. However, since the content is a detailed report on a specific agreement's performance over a period, and not just a general announcement, I will re-evaluate against the provided list. It is not a Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (CAP). It is a periodic report on market operations. In many jurisdictions, these are filed as regulatory announcements. Given the lack of a specific 'Liquidity Report' code, RNS is the best fit for a specific, non-standard regulatory disclosure.
2025-01-24 French
LUMIBIRD : CALENDRIER DE COMMUNICATION FINANCIÈRE
Report Publication Announcement Classification · 95% confidence The document is titled "CALENDRIER DE COMMUNICATION FINANCIÈRE" (Financial Communication Calendar) and lists future dates for key financial events like the release of 2024 annual revenue, 2024 annual results, Q1 2025 revenue, the Annual General Meeting (AGM), and H1 2025 results. It explicitly announces the upcoming publication of the 2024 annual revenue on 01/27/2025 and the 2024 annual results on 03/11/2025. Since the document's primary purpose is to announce *when* future reports and meetings will occur, rather than being the report itself (like a 10-K or ER), it fits best under the category for announcing report publications. Given the short length (2988 chars) and the focus on announcing future releases, Report Publication Announcement (RPA) is the most appropriate classification, although RNS is a possibility if RPA wasn't available. RPA is specifically defined for announcements regarding the timing/release of reports.
2025-01-24 French
LUMIBIRD: FINANCIAL COMMUNICATIONS AGENDA
Report Publication Announcement Classification · 95% confidence The document is titled 'FINANCIAL COMMUNICATIONS AGENDA' and explicitly lists future dates for key corporate events such as 'FY 2024 revenues', 'FY 2024 earnings', and 'Annual Shareholders Meeting'. This type of forward-looking schedule announcement, which informs investors about when future reports or meetings will occur, is best classified as an announcement regarding the publication of reports or general investor information. Since it is an announcement about future events rather than the report itself, and it doesn't fit perfectly into specific categories like ER or 10-K, it aligns best with Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the specific nature of announcing the schedule for future financial disclosures and the AGM, RPA is the most precise fit, as it announces the publication schedule of other reports.
2025-01-24 English
Lumibird : nombre de droits de vote et d'actions au 31 décembre 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is very short (911 characters) and presents a table detailing the total number of voting rights and shares as of December 31, 2024, referencing French regulations (Code de commerce and AMF General Regulation). This type of mandatory disclosure regarding the capital structure and voting rights is a specific regulatory filing. It is not a full report (10-K, IR), an earnings release (ER), or a management presentation (IP). Since it is a specific regulatory disclosure about share capital/voting rights that doesn't perfectly match the other specific codes (like DIRS or DIV), it falls best under the general regulatory announcement category, RNS, or potentially SHA (Share Issue/Capital Change) if interpreted broadly. However, given the focus is purely on the *count* of voting rights as required by specific articles, and it is a brief notification, RNS (Regulatory Filings) is the most appropriate fallback for specific, non-standard regulatory notices, although SHA is also plausible. Given the context of 'nombre total de droits de vote et d'actions', SHA (Share Issue/Capital Change) is a strong candidate as it relates directly to the capital structure, but RNS covers general regulatory notifications. Since the structure is a formal notification of the total number of shares/rights, which is a mandatory disclosure, I will classify it as RNS as it is a general regulatory filing notification.
2025-01-03 French
Lumibird : nombre de droits de vote et d'actions au 30 novembre 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is very short (893 characters) and presents a table detailing the total number of voting rights and shares as of November 30, 2024, referencing French regulatory articles (Code de commerce and AMF General Regulation). This type of mandatory disclosure regarding the total number of shares and voting rights is a specific regulatory filing requirement, often related to capital structure or shareholder information, but it does not fit perfectly into the main categories like 10-K, ER, or IR. It is a specific regulatory notice. Given the options, it most closely relates to capital structure updates or general regulatory announcements. Since it is a formal notification about the total number of shares and voting rights, it is a specific regulatory disclosure. It is not a dividend announcement (DIV), director dealing (DIRS), or a major shareholding notification (MRQ) which usually reports changes by an entity crossing a threshold. It is a formal statement of the current capital structure for voting purposes. This type of filing is often categorized under general regulatory filings or specific capital structure notices. Given the highly specific nature of the data (total voting rights), and lacking a perfect fit, it falls best under a general regulatory filing (RNS) or potentially a capital structure update (CAP). However, since it is a formal, periodic disclosure mandated by financial authorities regarding the total share count, RNS (Regulatory Filings) serves as the most appropriate general regulatory fallback for specific, non-periodic reports not covered elsewhere. It is not an announcement of a report (RPA).
2024-12-09 French
LUMIBIRD : PROJET EXPLORATOIRE DE VENTE DE LA DIVISION MEDICALE
Regulatory Filings Classification · 95% confidence The document is a short press release dated November 27, 2024, from LUMIBIRD announcing that it is exploring the potential sale of its Medical division following market rumors. This is a significant corporate event announcement that is not a full financial report (like 10-K or IR), a dividend notice, or an earnings release. It relates to a major strategic transaction, specifically a potential divestiture or sale of a business unit. Among the provided codes, 'TAR' (M&A Activity) is the most appropriate category for announcements related to mergers, acquisitions, takeovers, or significant divestitures/sales of business lines. Since the document is short and is an announcement of an exploratory process, it fits the nature of a corporate action disclosure.
2024-11-27 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.